Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Sustained release ophthalmological device and method of making and using the same

a technology of ophthalmological devices and suture release, which is applied in the field of ophthalmologic implants, can solve problems such as bulky intravitreal implants, and achieve the effect of reducing post-operative prescription drug costs and associated health care needs

Inactive Publication Date: 2006-11-02
SNYDER MICHAEL E +1
View PDF40 Cites 97 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021] The present invention contemplates not only methods of making ophthalmologic implants, but methods of implanting the implants into an eye (e.g., a human, a dog eye, horse eye or the like), therapies that employ the use of such an implant in an eye, as well as the implants themselves. The present invention affords numerous advantages including the elimination of a need or an implant recipient to receive prolonged post-operative therapy with topically applied pharmaceutical agents. In turn, this will help reduce post-operative prescription drug costs, and associated health care needs.

Problems solved by technology

Currently available delivery systems for intraocular therapeutics are generally limited to 1) drops, which carry issues of expense, inconvenience, patient noncompliance (by overuse, underuse, or inappropriate frequency of use) as well as difficulty for delivery of the medications by certain patients (especially those with arthritic conditions who cannot manipulate the vials properly); 2) injections; and 3) bulky intravitreal implants placed within the vitreous cavity of the eye, requiring incisions in the eye and delicate manipulations of the vitreous gel.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Sustained release ophthalmological device and method of making and using the same
  • Sustained release ophthalmological device and method of making and using the same
  • Sustained release ophthalmological device and method of making and using the same

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0026] In general, the ophthalmologic implants of the present invention will include at least one member, such as a filament, particularly one that is made of a biocompatible material that supports a pharmaceutical agent, and more preferably a pharmaceutical agent that is carried by a sustained release medium material, such as one selected from a bioerodible material, a biodegradable material, a bioavailable material or a mixture thereof.

[0027] The pharmaceutical agent herein may be a single agent, an admixture of agents, or multiple agents applied in simultaneous or serial coatings or layers. The pharmaceutical agent preferably is selected from an antibiotic, an anti-inflammatory, an antiglaucomatous, a steroid, or a combination thereof. By way of illustration (but without limitation to the employment of other unlisted agents), specific examples of pharmaceutical agents include 5-fluorouracil (5-FU), cyclosporine A (CsA), vancomycin, ganciclovir, fluocinolone acetonide, dexamethas...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
timeaaaaaaaaaa
timeaaaaaaaaaa
timeaaaaaaaaaa
Login to View More

Abstract

An ophthalmological implant including a layer of pharmaceutical agent and an overlying layer of a bioerodible material, a biodegradable material a bioavailable material or a mixture thereof.

Description

CLAIM OF BENEFIT OF FILING DATE [0001] The present application claims the benefit of the filing date of U.S. Provisional Application Ser. Nos. 60 / 349,465, filed Jan. 18, 2002, and 60 / 397,698, filed Jul. 22, 2002, the contents of which are hereby incorporated by reference for all purposes.TECHNICAL FIELD [0002] The present invention relates to ophthalmologic implants and more particularly to implants that incorporate a sustained release pharmaceutical agent, such as a steroid, an antibiotic, an anti-inflammatory agent, antiglaucomatous, or a combination thereof, BACKGROUND OF THE INVENTION [0003] Currently available delivery systems for intraocular therapeutics are generally limited to 1) drops, which carry issues of expense, inconvenience, patient noncompliance (by overuse, underuse, or inappropriate frequency of use) as well as difficulty for delivery of the medications by certain patients (especially those with arthritic conditions who cannot manipulate the vials properly); 2) inj...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61F2/00A61F2/02A61F2/14A61F2/16A61F9/00
CPCA61F2/147A61F2/1694A61F9/0017Y10S623/901A61F2210/0004A61F2250/0067A61F2250/0068A61F2002/1683A61F2/14A61F2/16A61K9/0051
Inventor SNYDER, MICHAEL E.DOBRUSIN, ERIC M.
Owner SNYDER MICHAEL E
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products